Among cell cycle checkpoint kinase genes, we observed 1.5-fold enrichment for ATM mutation (alone, not in combination with any other gene of interest) in primary ER+/HER2− breast cancer relative to metastatic disease (P = 0.003) (Fig. 5B). The gene discussed is ESR1; the disease is metastatic neoplasm.